Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.97 Insider Own3.90% Shs Outstand43.73M Perf Week-4.55%
Market Cap91.83M Forward P/E- EPS next Y-2.38 Insider Trans-50.93% Shs Float39.02M Perf Month-57.06%
Income-140.10M PEG- EPS next Q-0.76 Inst Own92.90% Short Float7.53% Perf Quarter-59.54%
Sales14.00M P/S6.56 EPS this Y-61.10% Inst Trans-0.02% Short Ratio3.97 Perf Half Y-67.49%
Book/sh4.42 P/B0.48 EPS next Y17.10% ROA-61.80% Target Price18.00 Perf Year-89.55%
Cash/sh3.13 P/C0.67 EPS next 5Y- ROE-78.00% 52W Range1.93 - 20.75 Perf YTD-71.58%
Dividend- P/FCF- EPS past 5Y- ROI-55.10% 52W High-89.88% Beta0.76
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin38.20% 52W Low8.81% ATR0.28
Employees169 Current Ratio4.30 Sales Q/Q354.50% Oper. Margin- RSI (14)26.07 Volatility6.19% 10.23%
OptionableYes Debt/Eq0.17 EPS Q/Q7.00% Profit Margin- Rel Volume0.37 Prev Close2.11
ShortableYes LT Debt/Eq0.16 EarningsAug 07 AMC Payout- Avg Volume740.38K Price2.10
Recom1.70 SMA20-29.55% SMA50-51.25% SMA200-70.81% Volume280,876 Change-0.47%
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Jul-18-19 09:16AM  Aclaris Therapeutics Enters Oversold Territory Zacks
Jul-16-19 01:25PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-10-19 11:35AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of (ACRS) Aclaris Therapeutics, Inc. ACCESSWIRE
Jul-09-19 12:15PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire +9.07%
10:33AM  Aclaris Shares Trade Higher On Patent Win For Facial Redness Drug Benzinga
09:00AM  What Makes Aclaris (ACRS) a New Buy Stock Zacks
07:00AM  Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% GlobeNewswire
Jul-07-19 09:30PM  Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Pintec, Sealed Air, and Aclaris Therapeutics on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Jul-05-19 03:59PM  Heres What Hedge Funds Think About Aclaris Therapeutics, Inc. (ACRS) Insider Monkey
Jul-03-19 04:01PM  Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors GlobeNewswire +5.56%
Jul-02-19 11:38AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jun-30-19 08:21AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Jun-28-19 06:45PM  INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
Jun-27-19 08:00PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -52.13%
01:09PM  Here's Why Aclaris Therapeutics Stock Collapsed Today Motley Fool
Jun-26-19 09:30PM  Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Aclaris Therapeutics, electroCore, Pintec, and Sealed Air on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
08:30PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire
05:54PM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire
04:55PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
04:01PM  Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints GlobeNewswire
10:45AM  FDA asks Chester County biopharm company to pull promotional video American City Business Journals
Jun-25-19 01:11PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jun-24-19 05:40PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire
02:53PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
12:02PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire
10:06AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aclaris Therapeutics, Inc. (ACRS) ACCESSWIRE
Jun-21-19 08:59PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire -9.02%
05:40PM  ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Aclaris Therapeutics, Inc. - ACRS Business Wire
04:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
Jun-17-19 01:16PM  Help may be on the way, via this Malvern biopharm firm, for male/female pattern baldness American City Business Journals
08:42AM  Aclaris Announces Positive Results From Alopecia Treatment Trial Benzinga
06:00AM  Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness) GlobeNewswire
Jun-14-19 04:01PM  Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference GlobeNewswire
Jun-07-19 10:41PM  Edited Transcript of ACRS earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents +5.33%
May-24-19 07:00AM  Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-17-19 09:05AM  Rigel Initiates Enrollment in Pivotal Blood Disorder Study Zacks
May-16-19 01:09PM  Aclaris Therapeutics, Inc. (ACRS) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 06:55PM  Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:46PM  Aclaris: 1Q Earnings Snapshot Associated Press
04:01PM  Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
May-07-19 03:03PM  How Do Analysts See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Performing In The Years Ahead? Simply Wall St.
May-01-19 07:00AM  Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-25-19 07:00AM  Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis GlobeNewswire +6.89%
Apr-24-19 07:00AM  Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata GlobeNewswire
Apr-05-19 03:04PM  Consider These 3 Falling Knives GuruFocus.com
Apr-03-19 10:47AM  Edited Transcript of ACRS earnings conference call or presentation 18-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-27-19 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conference GlobeNewswire
Mar-18-19 01:15PM  Aclaris Therapeutics, Inc. (ACRS) Q4 2018 Earnings Conference Call Transcript Motley Fool +20.43%
07:34AM  Aclaris: 4Q Earnings Snapshot Associated Press
07:00AM  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
06:00AM  Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-19 04:01PM  Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019 GlobeNewswire
Feb-28-19 07:00AM  Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg GlobeNewswire
Feb-19-19 07:00AM  Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology GlobeNewswire -7.01%
Jan-18-19 12:30PM  Should You Worry About Aclaris Therapeutics, Inc.s (NASDAQ:ACRS) CEO Salary Level? Simply Wall St.
Jan-02-19 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Dec-23-18 03:52AM  Do Hedge Funds Love Aclaris Therapeutics, Inc. (ACRS)? Insider Monkey
Dec-21-18 07:27AM  Aclaris Therapeutics Enters Oversold Territory Zacks
Dec-18-18 07:00AM  Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada CNW Group -10.00%
Dec-17-18 04:01PM  Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials GlobeNewswire
Dec-11-18 03:17PM  Top 6 Performing IPOs of 2015 (ONCE, GBT) Investopedia
Dec-03-18 07:00AM  Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan GlobeNewswire
Nov-28-18 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Nov-27-18 08:31AM  Aclaris Therapeutics (ACRS) Enters Oversold Territory Zacks
07:50AM  Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-18-18 11:51PM  Edited Transcript of ACRS earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-18 06:05PM  Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:01PM  Aclaris: 3Q Earnings Snapshot Associated Press
04:01PM  Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
Nov-02-18 04:01PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Oct-30-18 10:33AM  Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-18 04:01PM  Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire
Oct-23-18 01:27PM  One Thing To Remember About The Aclaris Therapeutics Inc (NASDAQ:ACRS) Share Price Simply Wall St.
Oct-22-18 04:01PM  Aclaris Announces Closing of Public Offering of Common Stock GlobeNewswire
Oct-19-18 12:53PM  Aclaris plans $92.9M public stock offering American City Business Journals
Oct-17-18 09:44PM  Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire
08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
Oct-16-18 07:27PM  Edited Transcript of ACRS earnings conference call or presentation 15-Oct-18 9:00pm GMT Thomson Reuters StreetEvents -7.08%
11:52AM  $65 million deal: Aclaris buying rights to rosacea drug from Allergan American City Business Journals
Oct-15-18 04:01PM  Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan GlobeNewswire
Oct-10-18 02:42PM  Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-03-18 07:00AM  Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference GlobeNewswire
Oct-02-18 07:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-01-18 04:01PM  Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA® (hydrogen peroxide) Topical Solution 40%, (w/w) GlobeNewswire
01:25PM  Aclaris partnership with St. Louis university targets aspiring scientists from underrepresented minority groups American City Business Journals
07:00AM  Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups GlobeNewswire
Sep-24-18 07:00AM  Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts GlobeNewswire
Sep-21-18 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Sep-17-18 07:00AM  Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting GlobeNewswire
Sep-05-18 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-21-18 07:00AM  Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research GlobeNewswire
Aug-16-18 07:40AM  Edited Transcript of ACRS earnings conference call or presentation 3-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-03-18 09:25AM  Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:15AM  Aclaris: 2Q Earnings Snapshot Associated Press
07:00AM  Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
06:00AM  Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 07:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-31-18 08:25AM  Recent Analysis Shows Solar Capital, Aclaris Therapeutics, Fidus Investment, NetApp, RLJ Lodging Trust, and AvalonBay Communities Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James E10% OwnerJun 27Sale2.69699,4751,882,077964,101Jul 01 05:01 PM
Flynn James E10% OwnerJun 26Sale4.501,7047,6711,072,775Jun 26 05:52 PM
Flynn James E10% OwnerJun 25Sale4.5151,484232,1361,073,127Jun 25 06:31 PM
Flynn James E10% OwnerJun 24Sale4.5263,240286,0031,083,761Jun 25 06:31 PM
Flynn James E10% OwnerJun 21Sale4.62339,5371,567,0991,096,824Jun 25 06:31 PM
Flynn James E10% OwnerMay 10Sale6.05180,5651,092,2741,166,959May 13 05:24 PM
Flynn James E10% OwnerMay 09Sale6.16434,1452,673,2481,238,828May 13 05:24 PM
Mehra AnandDirectorOct 22Buy10.75372,0934,000,0001,911,573Oct 23 07:13 PM
Tullman Stephen A.DirectorOct 04Buy14.007,10099,370177,457Oct 05 04:37 PM
Tullman Stephen A.DirectorAug 23Buy15.006,60098,985170,357Aug 27 04:46 PM
Tullman Stephen A.DirectorAug 15Buy15.976,25099,813163,757Aug 17 04:55 PM